NCT00591149

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase II Trial Of Oxaliplatin With Docetaxel Followed By Epidermal Growth Factor Antibody (EGFR-AB) Cetuximab In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size

Detailed description

This is a non-randomized, open-label, phase II study to assess the effects of oxaliplatin and docetaxel followed by epidermal factor-antibody (EGFR-AB) cetuximab on patients with previously treated recurrent /metastatic squamous cell carcinoma of the head and neck. Head and neck tissue will also be tested to determine if the protein Epidermal Growth Factor Receptor is present in the cancer cells.

Conditions

• Head and Neck Cancer
• Carcinoma, Squamous

Interventions

Type	Name	Description
DRUG	Oxaliplatin	130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
DRUG	Docetaxel	60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
DRUG	Cetuximab	400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks

Timeline

• Start date: 2007-06-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2008-01-11
• Last updated: 2017-06-14
• Results posted: 2017-06-14

Locations

1 site across 1 country: United States